1. ACOG Committee Opinion No. 432. (2009). Spinal muscular atrophy. Obstetrics and Gynecology, 113, 1194–1196.
2. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. (1995). ASHG/ACMG report: points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents. American Journal of Human Genetics, 57, 1233–1241.
3. Andreassi, C., Jarecki, J., Zhou, J., Coovert, D., Monani, U., Chen, X., et al. (2001). Aclarubicin treatment restores SMN levels to cell derived from type I spinal muscular atrophy patients. Human Molecular Genetics, 10, 2841–2849.
4. Bach, J. R., Baird, J. S., Plosky, D., Navado, J., & Weaver, B. (2002). Spinal muscular atrophy type 1: management and outcomes. Pediatric Pulmonology, 34, 16–22.
5. Baumbach-Reardon, L., Sacharow, S., & Ahearn, M. E. (2012). Spinal muscular atrophy, X-linked infantile. GeneReviews [Internet]. Retrieved from http://www.genetests.org/by-genereview .